{"pmid":32420938,"title":"What happens to people's lungs when they get coronavirus disease 2019?","text":["What happens to people's lungs when they get coronavirus disease 2019?","The novel coronavirus SARS-CoV-2 was first identified in Wuhan in December 2019 as cause of the consequent novel coronavirus disease 2019 (COVID-19). The virus has since spread worldwide. The clinical presentation following human infection ranges from a mild upper respiratory tract infection to severe acute respiratory distress syndrome and sepsis. We reviewed literature using Pubmed to identify relevant English-language articles published until April 15, 2020. Search terms include novel coronavirus pneumonia, severe acute respiratory syndrome coronavirus 2, coronavirus and ventilation. We summarized what SARS-CoV-2 infection means for the lungs.","Acta Biomed","Frizzelli, Annalisa","Tuttolomondo, Domenico","Aiello, Marina","Majori, Maria","Bertorelli, Giuseppina","Chetta, Alfredo","32420938"],"abstract":["The novel coronavirus SARS-CoV-2 was first identified in Wuhan in December 2019 as cause of the consequent novel coronavirus disease 2019 (COVID-19). The virus has since spread worldwide. The clinical presentation following human infection ranges from a mild upper respiratory tract infection to severe acute respiratory distress syndrome and sepsis. We reviewed literature using Pubmed to identify relevant English-language articles published until April 15, 2020. Search terms include novel coronavirus pneumonia, severe acute respiratory syndrome coronavirus 2, coronavirus and ventilation. We summarized what SARS-CoV-2 infection means for the lungs."],"journal":"Acta Biomed","authors":["Frizzelli, Annalisa","Tuttolomondo, Domenico","Aiello, Marina","Majori, Maria","Bertorelli, Giuseppina","Chetta, Alfredo"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420938","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.23750/abm.v91i2.9574","locations":["Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1667254896740532224,"score":9.490897,"similar":[{"pmid":32197787,"pmcid":"PMC7102628","title":"Practical recommendations for the perioperative management of the patient with suspection or serious infection by coronavirus SARS-CoV.","text":["Practical recommendations for the perioperative management of the patient with suspection or serious infection by coronavirus SARS-CoV.","In December 2019, the Wuhan Municipal Health and health Commission (Hubei Province, China) reported a series of cases of pneumonia of unknown etiology. On January 7, 2020, the Chinese authorities identified as a causative agent of the outbreak a new type of virus of the Coronaviridiae family, called SARS-CoV-2. Since then, thounsands of cases have been reported with global dissemination. Infections in humans cause a broad clinical spectrum ranging from mild upper respiratory tract infection, to severe acute respiratory distress syndrome and sepsis. There is not specific treatment for SARS-CoV-2, which is why the fundamental aspects are to establish adequate prevention measures and support treatment and management of complications.","Rev Esp Anestesiol Reanim","Montero Feijoo, A","Maseda, E","Adalia Bartolome, R","Aguilar, G","Gonzalez de Castro, R","Gomez-Herreras, J I","Garcia Palenciano, C","Pereira, J","Ramasco Rueda, F","Samso, E","Suarez de la Rica, A","Tamayo Medel, G","Varela Duran, M","32197787"],"abstract":["In December 2019, the Wuhan Municipal Health and health Commission (Hubei Province, China) reported a series of cases of pneumonia of unknown etiology. On January 7, 2020, the Chinese authorities identified as a causative agent of the outbreak a new type of virus of the Coronaviridiae family, called SARS-CoV-2. Since then, thounsands of cases have been reported with global dissemination. Infections in humans cause a broad clinical spectrum ranging from mild upper respiratory tract infection, to severe acute respiratory distress syndrome and sepsis. There is not specific treatment for SARS-CoV-2, which is why the fundamental aspects are to establish adequate prevention measures and support treatment and management of complications."],"journal":"Rev Esp Anestesiol Reanim","authors":["Montero Feijoo, A","Maseda, E","Adalia Bartolome, R","Aguilar, G","Gonzalez de Castro, R","Gomez-Herreras, J I","Garcia Palenciano, C","Pereira, J","Ramasco Rueda, F","Samso, E","Suarez de la Rica, A","Tamayo Medel, G","Varela Duran, M"],"date":"2020-03-22T11:00:00Z","year":2020,"_id":"32197787","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.redar.2020.03.003","keywords":["infeccion","infection","operating room","quirofano","recomendacion","recommendation","virus"],"locations":["China","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1666138490095534080,"score":156.22581},{"pmid":32498762,"title":"Coronavirus Disease 2019: Clinical Review.","text":["Coronavirus Disease 2019: Clinical Review.","INTRODUCTION: In December 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in Wuhan, the capital of Central China's Hubei Province and has been declared a public health emergency of international concern by the World Health Organization since January 2020. MATERIAL AND METHODS: A comprehensive search using the PubMed database was carried out to summarize the latest published information about the epidemiology, definition, pathogenesis, clinical characteristics, treatment options, prognosis and prevention of coronavirus disease 2019. DISCUSSION: This new strain of coronavirus, named severe acute respiratory syndrome coronavirus 2, enters human cells that express angiotensin-converting enzyme II receptors, which exist in the respiratory, gastrointestinal and genitourinary tracts and heart, causing coronavirus disease. Transmission occurs essentially through the respiratory tract and the main symptoms are fever, cough and dyspnea. Diagnosis is based on epidemiological, clinical and imaging features and confirmed by nucleic acid testing. CONCLUSION: Despite intensive research, the exact origin of the virus and pathophysiology of coronavirus disease is not yet completely known, and clinically approved vaccines and drugs that target severe acute respiratory syndrome coronavirus 2 are lacking.","Acta Med Port","Gouveia, Cristina Carvalho","Campos, Luis","32498762"],"abstract":["INTRODUCTION: In December 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in Wuhan, the capital of Central China's Hubei Province and has been declared a public health emergency of international concern by the World Health Organization since January 2020. MATERIAL AND METHODS: A comprehensive search using the PubMed database was carried out to summarize the latest published information about the epidemiology, definition, pathogenesis, clinical characteristics, treatment options, prognosis and prevention of coronavirus disease 2019. DISCUSSION: This new strain of coronavirus, named severe acute respiratory syndrome coronavirus 2, enters human cells that express angiotensin-converting enzyme II receptors, which exist in the respiratory, gastrointestinal and genitourinary tracts and heart, causing coronavirus disease. Transmission occurs essentially through the respiratory tract and the main symptoms are fever, cough and dyspnea. Diagnosis is based on epidemiological, clinical and imaging features and confirmed by nucleic acid testing. CONCLUSION: Despite intensive research, the exact origin of the virus and pathophysiology of coronavirus disease is not yet completely known, and clinically approved vaccines and drugs that target severe acute respiratory syndrome coronavirus 2 are lacking."],"journal":"Acta Med Port","authors":["Gouveia, Cristina Carvalho","Campos, Luis"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32498762","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.20344/amp.13957","keywords":["covid-19","coronavirus infections","severe acute respiratory syndrome"],"locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668804508822536193,"score":151.12497},{"pmid":32292686,"pmcid":"PMC7139198","title":"Coronavirus: Update Related to the Current Outbreak of COVID-19.","text":["Coronavirus: Update Related to the Current Outbreak of COVID-19.","In December 2019, some cases of viral pneumonia were epidemiologically related to a new coronavirus in the province of Hubei, China. Subsequently, there has been an increase in infections attributable to this virus throughout China and worldwide. The World Health Organization (WHO) has officially named the infection coronavirus disease 2019 (COVID-19), and the virus has been classified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This appears to be a virus from Rhinolophus bats, but the intermediate host has not yet been identified. The mechanism of infection of SARS-CoV-2 is not yet known; it appears to have affinity for cells located in the lower airways, where it replicates. The interhuman transmission of coronaviruses mainly occurs through saliva droplets and direct and indirect contact via surfaces. As of March 10, 2020, the number of cases worldwide was 113,702. Along with severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome (MERS), COVID-19 appears to cause a severe clinical picture in humans, ranging from mild malaise to death by sepsis/acute respiratory distress syndrome. The prognosis is worse in elderly patients with comorbidities. To date, there is no specific therapy for COVID-19. Prevention of SARS-CoV-2 infection implies strategies that limit the spread of the virus. WHO and other international and national bodies have developed continuously updated strategic objectives and provisions to contain the spread of the virus and infection.","Infect Dis Ther","Gabutti, Giovanni","d'Anchera, Erica","Sandri, Federica","Savio, Marta","Stefanati, Armando","32292686"],"abstract":["In December 2019, some cases of viral pneumonia were epidemiologically related to a new coronavirus in the province of Hubei, China. Subsequently, there has been an increase in infections attributable to this virus throughout China and worldwide. The World Health Organization (WHO) has officially named the infection coronavirus disease 2019 (COVID-19), and the virus has been classified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This appears to be a virus from Rhinolophus bats, but the intermediate host has not yet been identified. The mechanism of infection of SARS-CoV-2 is not yet known; it appears to have affinity for cells located in the lower airways, where it replicates. The interhuman transmission of coronaviruses mainly occurs through saliva droplets and direct and indirect contact via surfaces. As of March 10, 2020, the number of cases worldwide was 113,702. Along with severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome (MERS), COVID-19 appears to cause a severe clinical picture in humans, ranging from mild malaise to death by sepsis/acute respiratory distress syndrome. The prognosis is worse in elderly patients with comorbidities. To date, there is no specific therapy for COVID-19. Prevention of SARS-CoV-2 infection implies strategies that limit the spread of the virus. WHO and other international and national bodies have developed continuously updated strategic objectives and provisions to contain the spread of the virus and infection."],"journal":"Infect Dis Ther","authors":["Gabutti, Giovanni","d'Anchera, Erica","Sandri, Federica","Savio, Marta","Stefanati, Armando"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292686","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s40121-020-00295-5","keywords":["covid-19","coronavirus","infectious disease","mers","pneumonia","public health","sars","sars-cov-2"],"locations":["Hubei","China","China","Rhinolophus","Middle Eastern"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Mechanism","Diagnosis","Treatment"],"weight":1,"_version_":1666138494329683968,"score":148.2818},{"pmid":32469387,"title":"Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.","text":["Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review.","Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019, causing human coronavirus disease 2019 (COVID-19), which has now spread into a worldwide pandemic. The pulmonary manifestations of COVID-19 have been well described in the literature. Two similar human coronaviruses that cause Middle East respiratory syndrome (MERS-CoV) and severe acute respiratory syndrome (SARS-CoV-1) are known to cause disease in the central and peripheral nervous systems. Emerging evidence suggests COVID-19 has neurologic consequences as well. Observations: This review serves to summarize available information regarding coronaviruses in the nervous system, identify the potential tissue targets and routes of entry of SARS-CoV-2 into the central nervous system, and describe the range of clinical neurological complications that have been reported thus far in COVID-19 and their potential pathogenesis. Viral neuroinvasion may be achieved by several routes, including transsynaptic transfer across infected neurons, entry via the olfactory nerve, infection of vascular endothelium, or leukocyte migration across the blood-brain barrier. The most common neurologic complaints in COVID-19 are anosmia, ageusia, and headache, but other diseases, such as stroke, impairment of consciousness, seizure, and encephalopathy, have also been reported. Conclusions and Relevance: Recognition and understanding of the range of neurological disorders associated with COVID-19 may lead to improved clinical outcomes and better treatment algorithms. Further neuropathological studies will be crucial to understanding the pathogenesis of the disease in the central nervous system, and longitudinal neurologic and cognitive assessment of individuals after recovery from COVID-19 will be crucial to understand the natural history of COVID-19 in the central nervous system and monitor for any long-term neurologic sequelae.","JAMA Neurol","Zubair, Adeel S","McAlpine, Lindsay S","Gardin, Tova","Farhadian, Shelli","Kuruvilla, Deena E","Spudich, Serena","32469387"],"abstract":["Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019, causing human coronavirus disease 2019 (COVID-19), which has now spread into a worldwide pandemic. The pulmonary manifestations of COVID-19 have been well described in the literature. Two similar human coronaviruses that cause Middle East respiratory syndrome (MERS-CoV) and severe acute respiratory syndrome (SARS-CoV-1) are known to cause disease in the central and peripheral nervous systems. Emerging evidence suggests COVID-19 has neurologic consequences as well. Observations: This review serves to summarize available information regarding coronaviruses in the nervous system, identify the potential tissue targets and routes of entry of SARS-CoV-2 into the central nervous system, and describe the range of clinical neurological complications that have been reported thus far in COVID-19 and their potential pathogenesis. Viral neuroinvasion may be achieved by several routes, including transsynaptic transfer across infected neurons, entry via the olfactory nerve, infection of vascular endothelium, or leukocyte migration across the blood-brain barrier. The most common neurologic complaints in COVID-19 are anosmia, ageusia, and headache, but other diseases, such as stroke, impairment of consciousness, seizure, and encephalopathy, have also been reported. Conclusions and Relevance: Recognition and understanding of the range of neurological disorders associated with COVID-19 may lead to improved clinical outcomes and better treatment algorithms. Further neuropathological studies will be crucial to understanding the pathogenesis of the disease in the central nervous system, and longitudinal neurologic and cognitive assessment of individuals after recovery from COVID-19 will be crucial to understand the natural history of COVID-19 in the central nervous system and monitor for any long-term neurologic sequelae."],"journal":"JAMA Neurol","authors":["Zubair, Adeel S","McAlpine, Lindsay S","Gardin, Tova","Farhadian, Shelli","Kuruvilla, Deena E","Spudich, Serena"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32469387","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1001/jamaneurol.2020.2065","topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668167109909151746,"score":146.27855},{"pmid":32412918,"title":"COVID-19: A Worldwide, Zoonotic, Pandemic Outbreak.","text":["COVID-19: A Worldwide, Zoonotic, Pandemic Outbreak.","Context: An outbreak of a novel, zoonotic coronavirus occurred in December 2019 in the city of Wuhan, China and has now affected almost the entire world, with the maximum confirmed cases being 1 521 252 as of April 10, 2020. The WHO named this coronavirus 2019-nCoV, with COVID-19 being the name for diseases allied with it. Objective: The study intended to examine the features and characteristics of existing human coronaviruses and identify their resemblance to the newly identified 2019-nCoV. Design: The research team performed a literature review, searching relevant literature databases. We searched four databases, PubMed, EMBASE, Web of Science and CNKI (Chinese Database), to identify studies reporting COVID-19. Articles published on or before April 10, 2020 were eligible for inclusion. We used the following search terms: \"Coronavirus\" or \"2019-nCoV\" or \"COVID-19\" or \"SARS-CoV\" or \"MERS-CoV\" or \"Bat SARS-CoV\" or \"ACE2 receptor\". Setting: This study was take place in School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India. Results: The undistinguishable similarity of the genomic sequences of Severe Respiratory Syndrome (SARS)-CoV, Middle East Respiratory Syndrome (MERS)-CoV, and Bat SARS-CoV-bat-SL-CoVZC45 and bat-SL-CoVZXC21-to nCoV-2019 has facilitated the process of identifying primary treatment measures. Researchers are presuming the existence of angiotensin-converting enzyme 2 (ACE2) receptor binding in nCoV-2019, as in SARS-CoV. Researchers have been examining human-to-human transmission, the possibility of an intermediate host between bats and humans, and the existence of asymptomatic cases. An incubation period of 0 to 14 days has been reported, with acute to chronic symptoms being cough, nasal congestion, high fever, dyspnea, pneumonia, invasive lesions in both lungs, respiratory failure, and even death, including in pediatric cases. Mechanical ventilation, extracorporeal membrane oxygenation, repurposing of antivirals, and plasma infusion have proven to be somewhat effective. Several countries have started clinical trials to evaluate the safety and effectiveness of some drugs, but the ability to vaccinate people with existing or new molecules will require time. Previously learned lessons from SARS and MERS have led some areas to be well equipped in terms of the ability to take speedy action. Conclusions: First-level treatments include repurposing antivirals and antimalarials, and plasma infusion should help, but development of existing or new molecules into vaccines will take time. The unpredictable trajectory of this outbreak demands careful surveillance to monitor the situation, draw strategies, implement control measures, and create proper ethical laws and medical guidelines.","Altern Ther Health Med","Khan, Tahseen","Agnihotri, Kartikeya","Tripathi, Aditi","Mukherjee, Suneet","Agnihotri, Namita","Gupta, Gaurav","32412918"],"abstract":["Context: An outbreak of a novel, zoonotic coronavirus occurred in December 2019 in the city of Wuhan, China and has now affected almost the entire world, with the maximum confirmed cases being 1 521 252 as of April 10, 2020. The WHO named this coronavirus 2019-nCoV, with COVID-19 being the name for diseases allied with it. Objective: The study intended to examine the features and characteristics of existing human coronaviruses and identify their resemblance to the newly identified 2019-nCoV. Design: The research team performed a literature review, searching relevant literature databases. We searched four databases, PubMed, EMBASE, Web of Science and CNKI (Chinese Database), to identify studies reporting COVID-19. Articles published on or before April 10, 2020 were eligible for inclusion. We used the following search terms: \"Coronavirus\" or \"2019-nCoV\" or \"COVID-19\" or \"SARS-CoV\" or \"MERS-CoV\" or \"Bat SARS-CoV\" or \"ACE2 receptor\". Setting: This study was take place in School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India. Results: The undistinguishable similarity of the genomic sequences of Severe Respiratory Syndrome (SARS)-CoV, Middle East Respiratory Syndrome (MERS)-CoV, and Bat SARS-CoV-bat-SL-CoVZC45 and bat-SL-CoVZXC21-to nCoV-2019 has facilitated the process of identifying primary treatment measures. Researchers are presuming the existence of angiotensin-converting enzyme 2 (ACE2) receptor binding in nCoV-2019, as in SARS-CoV. Researchers have been examining human-to-human transmission, the possibility of an intermediate host between bats and humans, and the existence of asymptomatic cases. An incubation period of 0 to 14 days has been reported, with acute to chronic symptoms being cough, nasal congestion, high fever, dyspnea, pneumonia, invasive lesions in both lungs, respiratory failure, and even death, including in pediatric cases. Mechanical ventilation, extracorporeal membrane oxygenation, repurposing of antivirals, and plasma infusion have proven to be somewhat effective. Several countries have started clinical trials to evaluate the safety and effectiveness of some drugs, but the ability to vaccinate people with existing or new molecules will require time. Previously learned lessons from SARS and MERS have led some areas to be well equipped in terms of the ability to take speedy action. Conclusions: First-level treatments include repurposing antivirals and antimalarials, and plasma infusion should help, but development of existing or new molecules into vaccines will take time. The unpredictable trajectory of this outbreak demands careful surveillance to monitor the situation, draw strategies, implement control measures, and create proper ethical laws and medical guidelines."],"journal":"Altern Ther Health Med","authors":["Khan, Tahseen","Agnihotri, Kartikeya","Tripathi, Aditi","Mukherjee, Suneet","Agnihotri, Namita","Gupta, Gaurav"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32412918","source":"PubMed","week":"202020|May 11 - May 17","locations":["Wuhan","China","Chinese","Jaipur","India"],"countries":["China","India"],"countries_codes":["CHN|China","IND|India"],"topics":["Transmission","Mechanism","Treatment"],"weight":1,"_version_":1666989866131390465,"score":145.85739}]}